Robot Technology Identifies a Parkinsonian Therapeutics Repurpose to Target Stem Cells of Glioblastoma

Overview

Journal CNS Oncol

Specialty Oncology

Date 2020 May 29

PMID 32462934

Citations 10

Authors

Andres Vargas-Toscano

Dilaware Khan

Ann-Christin Nickel

Michael Hewera

Marcel Alexander Kamp

Igor Fischer

Hans-Jakob Steiger

Wei Zhang

Sajjad Muhammad

Daniel Hanggi

Ulf Dietrich Kahlert

Affiliations

Soon will be listed here.

Abstract

Glioblastoma is a heterogeneous lethal disease, regulated by a stem-cell hierarchy and the neurotransmitter microenvironment. The identification of chemotherapies targeting individual cancer stem cells is a clinical need. A robotic workstation was programmed to perform a drug concentration to cell-growth analysis on an model of glioblastoma stem cells (GSCs). Mode-of-action analysis of the selected top substance was performed with manual repetition assays and acquisition of further parameters. We identified 22 therapeutic potential substances. Three suggested a repurpose potential of neurotransmitter signal-modulating agents to target GSCs, out of which the Parkinson's therapeutic trihexyphenidyl was most effective. Manual repetition assays and initial mode of action characterization revealed suppression of cell proliferation, cell cycle and survival. Anti-neurotransmitter signaling directed therapy has potential to target GSCs. We established a drug testing facility that is able to define a mid-scale chemo responsome of cancer models, possibly also suitable for other cell systems.

Citing Articles

Muscarinic receptor drug trihexyphenidyl can alter growth of mesenchymal glioblastoma .

Du R, Sanin A, Shi W, Huang B, Nickel A, Vargas-Toscano A Front Pharmacol. 2024; 15:1468920.

PMID: 39386028 PMC: 11461351. DOI: 10.3389/fphar.2024.1468920.

The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H.

Mehjardi N, Kessler J, Sanin A, Picard D, Westhoff P, Nickel A Cell Death Discov. 2023; 9(1):452.

PMID: 38086797 PMC: 10716401. DOI: 10.1038/s41420-023-01747-w.

Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.

Alomari S, Zhang I, Hernandez A, Kraft C, Raj D, Kedda J Biomolecules. 2021; 11(12).

PMID: 34944514 PMC: 8699739. DOI: 10.3390/biom11121870.

Testing the Stability of Drug Resistance on Cryopreserved, Gene-Engineered Human Induced Pluripotent Stem Cells.

Khan D, Nickel A, Jeising S, Uhlmann C, Muhammad S, Hanggi D Pharmaceuticals (Basel). 2021; 14(9).

PMID: 34577619 PMC: 8466661. DOI: 10.3390/ph14090919.

A Preclinical Pipeline for Translational Precision Medicine-Experiences from a Transdisciplinary Brain Tumor Stem Cell Project.

Vargas-Toscano A, Janiak C, Sabel M, Kahlert U J Pers Med. 2021; 11(9).

PMID: 34575669 PMC: 8472761. DOI: 10.3390/jpm11090892.

References

Kahlert U, Suwala A, Raabe E, Siebzehnrubl F, Suarez M, Orr B . ZEB1 Promotes Invasion in Human Fetal Neural Stem Cells and Hypoxic Glioma Neurospheres. Brain Pathol. 2014; 25(6):724-32. PMC: 4470885. DOI: 10.1111/bpa.12240. View

Jiang S, Hu L, Wang X, Li J, Zhang Z . Neurotransmitters: emerging targets in cancer. Oncogene. 2019; 39(3):503-515. DOI: 10.1038/s41388-019-1006-0. View

Thompson E, Sontheimer H . Acetylcholine Receptor Activation as a Modulator of Glioblastoma Invasion. Cells. 2019; 8(10). PMC: 6829263. DOI: 10.3390/cells8101203. View

Venkataramani V, Tanev D, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T . Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019; 573(7775):532-538. DOI: 10.1038/s41586-019-1564-x. View

Skaga E, Kulesskiy E, Brynjulvsen M, Sandberg C, Potdar S, Langmoen I . Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. Clin Transl Med. 2020; 8(1):33. PMC: 6937360. DOI: 10.1186/s40169-019-0253-6. View

Beaulieu J, Gainetdinov R . The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011; 63(1):182-217. DOI: 10.1124/pr.110.002642. View

Caragher S, Shireman J, Huang M, Miska J, Atashi F, Baisiwala S . Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma. J Neurosci. 2019; 39(11):1982-1993. PMC: 6507082. DOI: 10.1523/JNEUROSCI.1589-18.2018. View

Fan X, Khaki L, Zhu T, Soules M, Talsma C, Gul N . NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells. 2009; 28(1):5-16. PMC: 2878196. DOI: 10.1002/stem.254. View

Skaga E, Kulesskiy E, Fayzullin A, Sandberg C, Potdar S, Kyttala A . Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma. BMC Cancer. 2019; 19(1):628. PMC: 6593575. DOI: 10.1186/s12885-019-5861-4. View

10.

Brancato V, Oliveira J, Correlo V, Reis R, Kundu S . Could 3D models of cancer enhance drug screening?. Biomaterials. 2020; 232:119744. DOI: 10.1016/j.biomaterials.2019.119744. View

11.

Kahlert U, Maciaczyk D, Dai F, Claus R, Firat E, Doostkam S . Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro. J Neuropathol Exp Neurol. 2012; 71(12):1086-99. DOI: 10.1097/NEN.0b013e3182772d83. View

12.

Lin A, Giuliano C, Palladino A, John K, Abramowicz C, Yuan M . Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019; 11(509). PMC: 7717492. DOI: 10.1126/scitranslmed.aaw8412. View

13.

Gorshkov K, Chen C, Marshall R, Mihatov N, Choi Y, Nguyen D . Advancing precision medicine with personalized drug screening. Drug Discov Today. 2018; 24(1):272-278. PMC: 6372320. DOI: 10.1016/j.drudis.2018.08.010. View

14.

The Lancet . Assessing researchers with a focus on research integrity. Lancet. 2019; 393(10181):1570. DOI: 10.1016/S0140-6736(19)30862-1. View

15.

Koch K, Hartmann R, Tsiampali J, Uhlmann C, Nickel A, He X . A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity. Cell Death Discov. 2020; 6:20. PMC: 7162917. DOI: 10.1038/s41420-020-0258-3. View

16.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

17.

Tseng H, Gage J, Shen T, Haisler W, Neeley S, Shiao S . A spheroid toxicity assay using magnetic 3D bioprinting and real-time mobile device-based imaging. Sci Rep. 2015; 5:13987. PMC: 4568483. DOI: 10.1038/srep13987. View